Literature DB >> 32063491

Postoperative nausea and vomiting after bariatric surgery and dexmedetomidine anesthetic: a propensity-weighted analysis.

S Chandralekha Kruthiventi1, Roger E Hofer1, Mary E Warner1, Juraj Sprung1, Todd A Kellogg2, Toby N Weingarten3.   

Abstract

BACKGROUND: Patients undergoing laparoscopic bariatric surgery have high rates of postoperative nausea and vomiting (PONV). Dexmedetomidine based anesthetic could reduce PONV rates.
OBJECTIVES: To determine if PONV rates differ in patients undergoing laparoscopic bariatric surgery with anesthesia primarily based on dexmedetomidine or standard anesthetic management with inhalational agents and opioids.
SETTING: University hospital.
METHODS: From January 2014 to April 2018, 487 patients underwent laparoscopic bariatric surgery and met inclusion criteria (dexmedetomidine, n = 174 and standard anesthetic, n = 313 patients). In both groups, patients received preoperative PONV prophylaxis. We analyzed rates of PONV and moderate-to-deep sedation. A propensity score was calculated and outcomes were assessed using generalized estimating equations with inverse probability of treatment weighting.
RESULTS: Perioperative opioids and volatile anesthetics were reduced in dexmedetomidine patients. During anesthesia recovery the incidence of PONV was similar between dexmedetomidine and standard anesthetic patients (n = 37 [21.3%] versus n = 61 [19.5%], respectively; inverse probability of treatment weighting odds ratio = 1.35; 95% confidence interval .78-2.32, P = .281), and the incidence of sedation higher in dexmedetomidine patients (n = 86 [49.4%] versus n = 75 [24.0%]; inverse probability of treatment weighting odds ratio = 2.43; 95% confidence interval 1.47-4.03, P < 0.001). Rates of PONV and sedation were similar during the remainder of the hospital stay. A secondary sensitivity analysis was performed limited to dexmedetomidine patients who did not receive volatile and results were similar.
CONCLUSIONS: While dexmedetomidine-based anesthesia was associated with reduced opioid and volatile agents use, it was not associated with a reduction of PONV. The higher rates of moderate-to-deep sedation during anesthesia recovery observed with dexmedetomidine may be undesirable in morbidly obese patients.
Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Dexmedetomidine; Postoperative nausea and vomiting; Postoperative sedation

Mesh:

Substances:

Year:  2020        PMID: 32063491     DOI: 10.1016/j.soard.2020.01.007

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  1 in total

1.  Effect of Dexmedetomidine Compared to Remifentanil During Bariatric Surgery on Postoperative Nausea and Vomiting: a Retrospective Study.

Authors:  Sun Woo Nam; Ah-Young Oh; Bon-Wook Koo; Bo Young Kim; Jiwon Han; Jiwon Yoon
Journal:  Obes Surg       Date:  2022-08-17       Impact factor: 3.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.